Bioverativ Inc.

The drug development focus in Duchenne muscular dystrophy (DMD) has been on gene therapy recently, but Dyne Therapeutics is working to develop next-generation exon-skipping medications that would co

Rare disease has become a real area of focus and growth for drug development. According to Citeline’s Pharma R&D Annual Review 2023 , more than 30% of all drug development is targeted against rar

A beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic

A beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic